Featured Story

  • Pfizer, 23andMe start building 5,000-person lupus database

    Pfizer and 23andMe have begun enrolling people in their lupus study. The partners aim to recruit 5,000 people into the study of the genetics of lupus over the next 12 months, in part by asking existing 23andMe customers to participate.

Bioinformatics leads UCSD team to ovarian cancer biomarkers

A team at the University of California, San Diego (UCSD), has found biomarkers for ovarian tumors by mining two National Institutes of Health-sponsored databases. The bioinformatics-enabled research program has raised expectations that earlier diagnoses of ovarian cancer can be made, an advance that could improve outcomes in a tough therapeutic indication.

CRISPR Therapeutics starts search for a bioinformatics chief

CRISPR Therapeutics has joined the hunt for bioinformatics talent. Fresh from a $64 million VC round, the CRISPR-Cas9 gene-editing startup is advertising for a head of bioinformatics, putting it in competition with multiple other biotechs that are trying to bolster their ranks of computational biologists.

UT Southwestern snags $5.6M grant to boost bioinformatics operation

The Cancer Prevention and Research Institute of Texas has given the University of Texas Southwestern Medical Center $5.6 million to build out its bioinformatics capabilities. Gaudenz Danuser, a professor UT Southwestern lured away from Harvard Medical School last year, is leading the initiative.

Genomics England searches for tumor sample processing improvements to boost data quality

Genomics England has run into teething problems in the first few months of its massive genome sequencing initiative. About half of tumor samples sequenced to date have yielded substandard data, a shortcoming Genomics England is trying to overcome by trialing new processes and working with hospitals to incorporate the practices into their day-to-day tasks.

Trialbee raises $5M to mount U.S. expansion of online trial enrollment business

Trialbee has raised $5 million to expand its clinical trial recruitment business in the U.S.


From Our Sister Sites


Bristol-Myers Squibb and rival Merck started off the big annual scientific meeting of  ASCO  with a bang, rolling out a slate of new studies spotlighting the growing body of evidence that their new immuno-oncology drugs will play a key role fighting a range of cancers.


Danish enzyme maker Novozymes is answering the call for alternatives to animal antibiotics by entering the market for probiotics--the so-called good bacteria that are believed to boost growth and prevent the buildup of bad bugs in animals' guts.